Literature DB >> 10871195

Validation of methods for measurement of insulin secretion in humans in vivo.

L L Kjems1, E Christiansen, A Vølund, R N Bergman, S Madsbad.   

Abstract

To detect and understand the changes in beta-cell function in the pathogenesis of type 2 diabetes, an accurate and precise estimation of prehepatic insulin secretion rate (ISR) is essential. There are two common methods to assess ISR, the deconvolution method (by Eaton and Polonsky)-considered the "gold standard"-and the combined model (by Vølund et al.). The deconvolution method is a 2-day method, which generally requires separate assessment of C-peptide kinetics, whereas the combined model is a single-day method that uses insulin and C-peptide data from a single test of interest. The validity of these mathematical techniques for quantification of insulin secretion have been tested in dogs, but not in humans. In the present studies, we examined the validity of both methods to recover the known infusion rates of insulin and C-peptide mimicking ISR during an oral glucose tolerance test. ISR from both the combined model and the deconvolution method were accurate, i.e., recovery of true ISR was not significantly different from 100%. Furthermore, both maximal and total ISRs from the combined model were strongly correlated to those obtained by the deconvolution method (r = 0.89 and r = 0.82, respectively). These results indicate that both approaches provide accurate assessment of prehepatic ISRs in type 2 diabetic patients and control subjects. A simplified version of the deconvolution method based on standard kinetic parameters for C-peptide (Van Cauter et al.) was compared with the 2-day deconvolution method, and a close agreement was found for the results of an oral glucose tolerance test. We also studied whether C-peptide kinetics are influenced by somatostatin infusion. The decay curves after bolus injection of exogenous biosynthetic human C-peptide, the kinetic parameters, and the metabolic clearance rate were similar whether measured during constant peripheral somatostatin infusion or without somatostatin infusion. Assessment of C-peptide kinetics can be performed without infusion of somatostatin, because the endogenous insulin concentration remains constant. Assessment of C-peptide kinetics with and without infusion of somatostatin results in nearly identical secretion rates for insulin during an oral glucose tolerance test.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871195     DOI: 10.2337/diabetes.49.4.580

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  17 in total

1.  Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes.

Authors:  D H Jensen; K Aaboe; J E Henriksen; A Vølund; J J Holst; S Madsbad; T Krarup
Journal:  Diabetologia       Date:  2012-05       Impact factor: 10.122

2.  Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.

Authors:  F K Knop; T Vilsbøll; S Madsbad; J J Holst; T Krarup
Journal:  Diabetologia       Date:  2007-01-16       Impact factor: 10.122

Review 3.  Motivations and methods for analyzing pulsatile hormone secretion.

Authors:  Johannes D Veldhuis; Daniel M Keenan; Steven M Pincus
Journal:  Endocr Rev       Date:  2008-10-21       Impact factor: 19.871

4.  Reduction in added sugar intake and improvement in insulin secretion in overweight latina adolescents.

Authors:  Jaimie N Davis; Emily E Ventura; Gabriel Q Shaibi; Marc J Weigensberg; Donna Spruijt-Metz; Richard M Watanabe; Michael I Goran
Journal:  Metab Syndr Relat Disord       Date:  2007-06       Impact factor: 1.894

5.  High heritability and genetic correlation of intravenous glucose- and tolbutamide-induced insulin secretion among non-diabetic family members of type 2 diabetic patients.

Authors:  Anette P Gjesing; Malene Hornbak; Kristine H Allin; Claus T Ekstrøm; Søren A Urhammer; Hans Eiberg; Oluf Pedersen; Torben Hansen
Journal:  Diabetologia       Date:  2014-03-07       Impact factor: 10.122

6.  GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study.

Authors:  Lærke S Gasbjerg; Mikkel B Christensen; Bolette Hartmann; Amalie R Lanng; Alexander H Sparre-Ulrich; Maria B N Gabe; Flemming Dela; Tina Vilsbøll; Jens J Holst; Mette M Rosenkilde; Filip K Knop
Journal:  Diabetologia       Date:  2017-09-25       Impact factor: 10.122

7.  Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance.

Authors:  Marie Eriksen; David H Jensen; Siri Tribler; Jens J Holst; Sten Madsbad; Thure Krarup
Journal:  Diabetologia       Date:  2015-03-09       Impact factor: 10.122

Review 8.  Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors:  Cornelia B Landersdorfer; William J Jusko
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

9.  Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes.

Authors:  P V Højberg; M Zander; T Vilsbøll; F K Knop; T Krarup; A Vølund; J J Holst; S Madsbad
Journal:  Diabetologia       Date:  2008-02-22       Impact factor: 10.122

10.  Effect of sitagliptin on glucose control in type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery.

Authors:  Ankit Shah; Kiarra Levesque; Esmeralda Pierini; Betsy Rojas; Michael Ahlers; Sarah Stano; Marlena Holter; Roxanne Dutia; Scott Belsley; James McGinty; Blandine Laferrère
Journal:  Diabetes Obes Metab       Date:  2017-11-28       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.